Dulaglutide
Once-weekly GLP-1 receptor agonist Fc-fusion protein (Trulicity) that reduces HbA1c by 1.5–1.9%, promotes 3–4.6 kg weight loss, and demonstrated cardiovascular event reduction in the REWIND trial — available in convenient pre-filled autoinjector with no reconstitution required
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
0.75 – 4.5 mg
0.75 mg
4 weeks before increasing
1.5 mg
Ongoing
3.0–4.5 mg
Ongoing
Compound profile
Scientific & efficacy data
Weight Management
Peptide profile
Strong human trials
Dulaglutide
0.75 mg · Once weekly
Molecular formula
C2646H4044N704O836S18 (complete fusion protein homodimer)
- Mol. weight
- ~63 kDa (~59,670 Da per chain)
- CAS number
- 923950-08-7
- PubChem
- Not available (large fusion protein)
- Developed · 2014 (initial FDA approval); 2020 (higher doses 3.0 and 4.5 mg); 2022 (CV outcomes indication)
- Eli Lilly Research Team
Eli Lilly and Company
Amino acid sequence
Modified GLP-1(7-37)-[Gly-Ser]13-IgG4-Fc homodimerMetabolic
Delivers robust glycemic control with HbA1c reduction of 1.5–1.9% across the 11-trial AWARD program, superior or non-inferior to most diabetes comparators — with higher doses (3.0 and 4.5 mg) providing even greater efficacy and proven cardiovascular event reduction
Weight Management
Promotes dose-dependent weight loss of 3.0–4.6 kg with cardiovascular risk factor improvements including cholesterol reduction (≤6.0%), VLDL reduction (≤19.4%), triglyceride reduction (≤21.5%), and systolic blood pressure lowering (up to 5.6 mmHg)
Healing & Recovery
REWIND trial demonstrated reduction in major adverse cardiovascular events, earning an FDA-approved cardiovascular outcomes indication — providing long-term cardioprotection in type 2 diabetes patients with or without established CVD
Dosing
How much do I take?
0.75 mg, titrated to 3.0–4.5 mg · once weekly
0.75 – 4.5 mg
Once weekly
Covers all 3 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control & patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection
Best for
Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
Dulaglutide is particularly well-suited for individuals focused on type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
Dulaglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
Dulaglutide is particularly well-suited for individuals focused on overweight or obese t2dm patients requiring both weight loss and hba1c reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pediatric patients aged 10–17 with type 2 diabetes (approved indication)
Dulaglutide is particularly well-suited for individuals focused on pediatric patients aged 10–17 with type 2 diabetes (approved indication). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Dulaglutide with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Subcutaneous injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Dulaglutide is an FDA-approved GLP-1 receptor agonist carrying a black box warning for thyroid C-cell tumor risk, based on rodent data showing increased medullary thyroid cancer (MTC) in rat models.
This risk is contraindicated in patients with personal or family history of MTC or multiple endocrine neoplasia type 2. Nausea occurs in 20-40% of patients, particularly dose-dependent and most severe at initiation; gastrointestinal side effects (vomiting, diarrhea) are common.
Pancreatitis has been reported in 0.1-0.2% of patients—discontinue immediately if severe abdominal pain develops. Rapid weight loss can trigger gallstone formation. Dehydration risk is significant, especially with concurrent SGLT2 inhibitors. Injection site reactions are mild but frequent.
Dulaglutide was studied through Phase 3 randomized controlled trials for type 2 diabetes (AWARD program) with thousands of patients, providing robust safety data. The FDA black box warning reflects preclinical evidence in animal models combined with post-market surveillance over 10+ years.
Comparative efficacy and safety trials with other GLP-1 agonists (semaglutide, liraglutide) provide substantial evidence base for risk-benefit analysis.
Common side effects · experienced by some users
Nausea
Occurs in 13.4–16.4% of patients depending on dose. Generally mild to moderate, most pronounced during the first weeks and dose escalation. Lower incidence than many other GLP-1 RAs.
Management: Gradual dose titration over 4-week intervals. Eat smaller, more frequent meals. Most patients develop tolerance within 4–6 weeks. Nausea rates with dulaglutide are among the lowest in the GLP-1 RA class.
Diarrhea and abdominal pain
Common GI effects of GLP-1 receptor activation affecting the gastrointestinal tract. Usually mild to moderate and self-limiting.
Management: Stay hydrated. Dietary adjustments as needed. Generally improves with continued therapy.
Vomiting
Reported in 5.6–9.3% of patients, dose-dependent. More common during dose escalation periods.
Management: Ensure gradual dose titration. Temporarily hold at current dose if persistent. Consider anti-emetics short-term if needed.
Decreased appetite
Reduced appetite is a pharmacological effect of central GLP-1 receptor activation and contributes to the weight loss benefit of dulaglutide.
Management: Generally considered a therapeutic benefit. Ensure adequate nutrition is maintained despite reduced appetite.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Dulaglutide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Dulaglutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Metformin (foundational combination for type 2 diabetes with additive glycemic benefit — used as background therapy in most AWARD trials) — May be used together under medical guidance.
- Safe:SGLT2 inhibitors (empagliflozin, dapagliflozin) — complementary cardiovascular and renal protection through different mechanisms with synergistic weight loss — May be used together under medical guidance.
- Safe:Basal insulin (for patients requiring additional glycemic control beyond dulaglutide monotherapy; monitor for hypoglycemia) — May be used together under medical guidance.
With medications
- Caution:Other GLP-1 receptor agonists (liraglutide, semaglutide, exenatide) — redundant mechanism with increased adverse effects and no additional benefit — Use with caution—discuss with your healthcare provider.
- Caution:DPP-4 inhibitors — overlapping incretin pathway mechanism without additional glycemic benefit — Use with caution—discuss with your healthcare provider.
- Caution:Sulfonylureas or insulin at full dose — increased hypoglycemia risk; dose reduction of insulin secretagogues required when initiating dulaglutide — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Dulaglutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-4 (initiation at 0.75 mg)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved for this use
Onset of effects
Gradual
(3-4 weeks)
How it works
Dulaglutide (Trulicity) is a once-weekly GLP-1 hormone mimic that helps your pancreas release insulin when blood sugar is high, slows stomach emptying to reduce appetite, and activates your brain's appetite control center—delivering powerful blood sugar control and steady weight loss.
The deeper mechanism
Dulaglutide is a 63-kDa fusion protein composed of modified human GLP-1(7-37) analog (with Ala8Gly, Gly22Glu, Arg36Gly substitutions) covalently linked via a 13-amino acid GGGGGGGSGGGGSG linker to the modified human IgG4 Fc domain, forming a homodimeric structure.
This design provides FcRn-mediated recycling and extended half-life (~5 days) while preserving potent GLP-1 receptor agonism.
Dulaglutide activates GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion, suppresses glucagon from alpha cells in hyperglycemic states, delays gastric emptying via vagal signaling, and activates central GLP-1 receptors in the hypothalamus to promote satiety and suppress food intake.
What to expect
Weeks 1-4 (initiation at 0.75 mg)
What you might notice
- Mild nausea that typically appears during the first 1–2 weeks and improves
- Reduced appetite and early feelings of fullness after meals
- Initial modest improvements in blood glucose levels
- Early weight loss (0.5–1 kg) from reduced caloric intake
What's normal
- GI side effects are most common during initiation but tend to be milder than with many other GLP-1 RAs
- The 0.75 mg starting dose provides sub-maximal glycemic benefit — full effect comes at higher doses
- Once-weekly dosing means drug levels build gradually toward steady state over 2–4 weeks
- The autoinjector pen simplifies the weekly injection without reconstitution
What's next
- If tolerated, increase to 1.5 mg weekly at week 4 or later
- GI side effects should continue improving with time
- Blood glucose monitoring will show progressive improvement
Weeks 4-16 (dose optimization and early maintenance)
What you might notice
- Significant HbA1c improvement (typically 1.0–1.5% reduction by 12–16 weeks)
- Progressive weight loss of 2–3 kg at the 1.5 mg dose
- Resolution of most GI side effects from the initiation phase
- Improved energy and metabolic well-being
What's normal
- Glycemic improvements continue to build as steady-state drug levels are established
- Weight loss progresses steadily alongside maintained appetite suppression
- If additional glycemic control is needed, higher doses (3.0 or 4.5 mg) can be considered
- Cardiovascular benefits are accumulating through metabolic improvements
What's next
- Evaluate HbA1c response at 12–16 weeks to determine if dose escalation is beneficial
- Continue lifestyle modifications (diet, exercise) to enhance therapeutic effect
- Consider adding SGLT2 inhibitor if additional glycemic or renal benefit is desired
Months 4-12+ (long-term maintenance)
What you might notice
- Sustained HbA1c reduction of 1.5–1.9% from baseline
- Stable weight loss of 3.0–4.6 kg depending on dose and individual response
- Improved lipid profile and blood pressure measurements
- Consistent weekly routine with minimal side effects
What's normal
- Weight loss rate naturally plateaus after 6–12 months — this is expected metabolic adaptation
- Glycemic benefits remain stable with continued therapy
- REWIND data supports long-term cardiovascular protection with ongoing use
- Annual monitoring of HbA1c, renal function, lipids, and cardiovascular risk factors
What's next
- Continue long-term therapy for sustained cardiometabolic benefits
- Higher doses (3.0 or 4.5 mg) available if additional efficacy is desired
- Periodic comprehensive metabolic and cardiovascular assessment
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Dulaglutide over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
127 registered studies, 13 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 58,872 people took part in the studies that actually administered Dulaglutide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
ProGen. Co., Ltd.
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
First Affiliated Hospital of Wannan Medical College
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Dulaglutide is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
What makes dulaglutide different from other GLP-1 receptor agonists?
Dulaglutide is unique in its molecular design — it is a GLP-1 analog fused to a modified IgG4 Fc fragment, creating a large (~63 kDa) fusion protein that resists both DPP-4 degradation and renal clearance. This provides a true 5-day half-life enabling once-weekly dosing. It also comes in a ready-to-use pre-filled autoinjector pen that requires no reconstitution, making it one of the simplest GLP-1 RA injection methods available.
What dose strengths are available for dulaglutide?
Dulaglutide is available in four dose strengths: 0.75 mg (starting dose), 1.5 mg (standard dose), 3.0 mg, and 4.5 mg (higher doses approved in 2020 for enhanced efficacy). AWARD-11 showed that 4.5 mg provides superior HbA1c reduction (-1.77% vs -1.54%) and weight loss (-4.6 kg vs -3.0 kg) compared to 1.5 mg.
Can children use dulaglutide?
Yes, dulaglutide (Trulicity) is FDA-approved for type 2 diabetes in youth aged 10 to less than 18 years based on the AWARD-PEDS trial. This trial showed 51% of dulaglutide-treated patients achieved HbA1c <7.0% compared to 14% with placebo, making it an effective option for pediatric type 2 diabetes.
Does dulaglutide protect against cardiovascular disease?
Yes. The REWIND trial demonstrated that dulaglutide reduces major adverse cardiovascular events in adults with type 2 diabetes, leading to an FDA-approved cardiovascular outcomes indication in June 2022. Higher doses also show dose-dependent improvements in cholesterol, triglycerides, and blood pressure.
Can dulaglutide be used in patients with kidney disease?
Yes. No dose adjustment is required for any degree of renal or hepatic impairment. The AWARD-7 trial specifically demonstrated dulaglutide's efficacy in patients with chronic kidney disease, showing non-inferior glycemic control to insulin glargine with a favorable renal safety profile.
How does dulaglutide compare to semaglutide for weight loss?
Semaglutide generally produces greater weight loss than dulaglutide — up to 15% of body weight at the highest doses (Wegovy 2.4 mg) versus 3–5% with dulaglutide. However, dulaglutide has its own FDA-approved cardiovascular outcomes indication, a convenient autoinjector pen, and the broadest range of dose options (0.75–4.5 mg weekly) among GLP-1 RAs, allowing flexible dose optimization.
Further reading
History & related research
History · since 2005
The Antibody Shield That Made Once-a-Week Possible
By fusing a gut hormone to an antibody fragment, Eli Lilly's engineers created a drug that lasts an entire week on a single injection — turning a daily burden into a Sunday morning routine for millions of people with diabetes.
Read the full history of DulaglutideStudied for
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Dulaglutide, on one page.